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Abstract
Background: Variation in the effects of genetic variants on physiological traits over time or with age may alter the
trajectories of these traits. However, few studies have investigated this possibility for variants associated with type 2
diabetes or obesity, and these show little consensus. We aimed to characterise the possible longitudinal
associations of common diabetes-susceptibility variants in the KCNJ11, PPARG, TCF7L2, IGF2BP2, CDKAL1, SLC30A8
and HHEX gene loci, with fasting glucose level; and of an obesity-associated variant in the FTO gene, with body
mass index (BMI).
Methods: The study analysed data from the Busselton Health Study (n = 4,554). Cross-sectional association
analyses included family data and used the total association test. Longitudinal association analyses of unrelated
participant data (n = 2,864) used linear mixed-effects models.
Results: In cross-sectional analyses, we observed associations of the T allele at the IGF2BP2 single nucleotide
polymorphism (SNP) rs4402960 with raised fasting glucose (p = 0.045), and the A allele at the FTO SNP rs9939609
with raised BMI (p = 0.003). Longitudinal analyses showed no significant associations between SNPs and changes
in fasting glucose or BMI in the same individuals, either over mean follow-up times of 18.7 and 21.8 years
respectively, or with age during adulthood.
Conclusions: There was no indication that the effects of common type 2 diabetes variants on fasting glucose
varied with age during adulthood or over time.
Background
Physiological traits are frequently dynamic, varying over
time with changing or accumulating environmental and
physiological factors. The influence of genotype on these
traits may also vary over time through interaction with
factors such as age, developmental stage or time-depen-
dent environmental factors. Variation in the effects of
genetic variants at different stages of life could signifi-
cantly alter the trajectories of traits and potentially also
the risks of certain diseases. Hence, studies that do not
consider the possibility of longitudinal variation in
genetic associations may lead to over-simplistic models
of variant effects.
Type 2 diabetes (T2D) is a complex disease with
numerous risk factors, including a growing number of
known genetic susceptibility variants [1-4]. The risk of
T2D also rises with increasing age [5]. Some of the inter-
mediate traits of T2D, such as obesity and raised fasting
plasma glucose, similarly have complex determinants and
indeed both BMI and fasting plasma glucose also tend to
increase with age [6,7]. These observations raise the
question of whether time- or age-varying genetic effects
e x i s tt h a tc o u l di n f l u e n c es u c hi n t e r m e d i a t et r a i t sa n d
thereby T2D risk.
To date, there have been few studies of the longitudinal
effects of T2D- or obesity-susceptibility variants. Those
that have examined the longitudinal effects of the FTO
variant rs9939609 with BMI, give mixed results [8-13].
This SNP has been shown through cross-sectional studies
to be robustly associated with raised BMI and, likely
as a result of this effect, also linked to the risk of
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any medium, provided the original work is properly cited.T2D [3,11,14-16]. Some longitudinal studies also provide
evidence of an age-dependent relationship between
rs9939609 and BMI whilst others do not, and some were
performed in children and some in adults [8-13].
In the present study, we tested the cross-sectional and
longitudinal associations of common genetic variants
shown to be associated with the risk of T2D and/or
raised BMI [1-4,14,15,17-20], with fasting glucose levels
and BMI. The study utilisedd a t af r o mt h eB u s s e l t o n
Health Study (BHS), in which participants have com-
pleted an average of 3.9 phenotypic surveys each, over
an average follow-up time of 21.2 years (95% CI 13.6-
28.8 years). The variants selected were the potassium
inwardly-rectifying channel J11 (KCNJ11)s i n g l en u c l e o -
tide polymorphism (SNP) rs5219 (E23K variant); the
peroxisome proliferator-activated receptor gamma
(PPARG) SNP rs1801282 (Pro12Ala variant); the tran-
scription factor 7-like 2 (TCF7L2) SNP rs7903146; the
insulin-like growth factor 2 mRNA binding protein 2
(IGF2BP2) SNP rs4402960; the CDK5 regulatory subunit
associated protein1-like 1 (CDKAL1) SNP rs10946398;
the solute carrier family 30 (zinc transporter), member 8
(SLC30A8) SNP rs13266634; the hematopoietically
expressed homeobox (HHEX) SNP rs1111875; and the
fat mass and obesity associated (FTO) SNP rs9939609.
These variants represent those with the strongest
reported effects on type 2 diabetes risk and, for the FTO
variant, BMI.
Methods
Participants
Participants were part of the BHS. The BHS includes a
series of seven cross-sectional population health surveys of
adult residents of the Shir eo fB u s s e l t o ni nW e s t e r n
Australia, conducted between 1966 and 1990, plus a
follow-up study of all survivors of previous surveys, con-
ducted in 1994/95 [21-23]. The population is predomi-
nantly European-Australian. The 1994/95 follow-up study
involved 4,554 participants from 696 families, and
included the collection of blood samples to be used for
DNA extraction. Population descriptives for participants
surveyed in the 1994/95 follow-up have been presented
elsewhere [24] and are reproduced here in Table 1 with
kind permission of Springer Science+Business Media.
2,864 unrelated individuals, each of whom had partici-
pated in at least one of the eight cross-sectional surveys
while aged between 18 and 80 years, were selected from
this cohort for longitudinal analysis. A subset of this unre-
lated sub-cohort, comprising only the 2,583 individuals
that reported never having been diagnosed with diabetes
and had no fasting glucose level measurements greater
than or equal to 7 mmol/L, was also selected, for longitu-
dinal analysis of the fasting glucose outcome variable only.
Descriptives for individuals in the unrelated sub-cohort
have been presented elsewhere [24] and are reproduced
here in Table 2 with kind permission of Springer Science+
Business Media. The mean number of survey attendances
for these individuals was 3.9 (standard error of the mean
0.04), over a mean follow-up time of 21.2 years (95% confi-
dence interval (CI) 13.6-28.8 years). Measurements of
BMI, fasting glucose, triacylglycerol and high-density lipo-
protein (HDL) levels were taken at 8, 7, 6 and 4 surveys
respectively. The subset of unrelated participants had aver-
age follow-up times of 21.8, 18.7, 17.0 and 15.1 years for
these measurements, respectively. All participants gave
written informed consent. The Human Research Ethics
Committee of the University of Western Australia
approved all study protocols.
Clinical measurements
Clinical measurements were taken as described previously
[21,22]. A self-administered questionnaire was used
to determine participants’ history of smoking, physician-
diagnosed diabetes and use of lipid-lowering medication
and insulin injections. Anthropomorphic measurements
were taken according to standard clinical procedures. The
presence of coronary heart disease was determined
using the Rose questionnaire, electrocardiogram and
Table 1 Description of the BHS whole study population
at the 1994/95 survey (n = 4,554)
a
Variable (units) Mean (SD)
Age (years) 50.6 (17.2)
BMI (kg/m
2) 26.0 (4.2)
Fasting glucose (mmol/l) 5.0 (1.4)
Triacylglycerol (mmol/l) 1.3 (0.9)
LDL (mmol/l) 3.6 (1.0)
HDL (mmol/l) 1.4 (0.4)
Total cholesterol (mmol/l) 5.6 (1.1)
SBP (mmHg) 124.1 (17.9)
DBP (mmHg) 74.5 (10.2)
Male, % (n) 44.2 (2014)
Smoking (ever smoked), % (n) 17.7 (805)
Diabetes (ever had diabetes), % (n) 6.0 (271)
Obesity (BMI ≥ 30), % (n) 13.3 (726)
Coronary heart disease, % (n) 16.3 (744)
Metabolic syndrome (IDF definition), % (n) 19.1 (871)
Metabolic syndrome (NCEP definition), % (n) 15.9 (722)
Lipid-lowering medication, % (n) 2.5 (116)
Insulin injections, % (n) 0.7 (31)
IDF, International Diabetes Federation; NCEP, National Cholesterol Education
Program.
a Originally published as Table 1 in Webster RJ, Warrington NM, Weedon MN,
Hattersley AT, McCaskie PA, Beilby JP, Palmer LJ, Frayling TM: The association
of common genetic variants in the APOA5, LPL and GCK genes with
longitudinal changes in metabolic and cardiovascular traits. Diabetologia 2009,
52(1):106-114,
© Springer-Verlag 2008, reproduced here with kind permission
of Springer Science+Business Media.
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myocardial infarction.
Laboratory measurements
Fasting glucose, insulin and lipid (HDL, low-density
lipoprotein (LDL) and triacylglycerol) levels were mea-
sured from fasting venous blood samples as described
previously [25]. The HOMA Calculator [26] was used to
calculate homeostatic model assessment (HOMA) scores
to be used as indicators of insulin resistance. These
were HOMA2-%B (steady-state beta cell function) and
HOMA2-%S (insulin sensitivity) [27,28].
Genes and genotyping
The SNPs selected for this study were the KCNJ11 SNP
rs5219; the PPARG SNP rs1801282; the TCF7L2 SNP
rs7903146; the IGF2BP2 SNP rs4402960; the CDKAL1
SNP rs10946398; the SLC30A8 SNP rs13266634; the
HHEX SNP rs1111875; and the FTO SNP rs9939609.
These SNPs were genotyped for all 4,554 study partici-
pants using TaqMan probes designed and supplied by
Applied Biosystems, Scoresby, VIC Australia. All primer
sequences and experimental conditions are available
from the authors on request. Genotyping was performed
by the PathWest Molecular Genetics Service, Nedlands,
WA, Australia.
Statistical analyses
The statistical analysis approach and methods used for
this study are as described in detail elsewhere [24].
Tests of Hardy-Weinberg equilibrium were conducted
using an exact test implemented in the statistical analy-
sis package, R [29].
Cross-sectional association analyses were performed
using 1994/95 survey data from the whole cohort of
4,554 participants. The continuous outcome variables
tested were HDL, LDL, triacylglycerol, systolic blood
pressure (SBP), diastolic blood pressure (DBP), fasting
glucose and fasting insulin levels, HOMA2-%B,
HOMA2-%S, and BMI. With the exception of LDL and
DBP, all were natural log-transformed prior to analysis.
The binary outcome variables tested were ‘history of
diabetes’, a variable indicating whether a participant had
reported ever been diagnosed with diabetes at any sur-
vey, and ‘obesity’, a variable indicating whether a partici-
pant was obese (BMI ≥ 30) at the 1994/95 survey.
Selection of covariates for each outcome involved the
use of generalised linear models to model the effects of
a set of multiple relevant phenotypes on the outcome in
the unrelated sub-cohort, using the SimHap v1.0.0 pro-
gram http://www.genepi.org.au/simhap.html, and a pro-
cess of stepwise elimination to remove those not
associated with the outcome. Models derived using this
procedure were called full covariate models. Simple cov-
ariate models including only sex and age were also used
for analyses. Cross-sectional association analyses of con-
tinuous outcomes employed the total association test as
implemented in the QTDT v2.6.0 program [30]. This
test models the effects of covariates on continuous out-
comes within families. Between-individual variance was
modelled by environmental, polygenic and additive
major-gene-effect variance components. Cross-sectional
analysis of the binary obesity outcome employed the
transmission disequilibrium test (TDT) as implemented
in the QTDT v2.6.0 program. As there were too few
participants with a history of diabetes in the whole
cohort to enable a TDT of family data to be performed
for all SNPs, cross-sectional analyses of the history of
diabetes outcome were performed on the sub-cohort of
unrelated participants aged 18-80 years, using the Sim-
Hap v1.0.0 program to fit generalised linear models.
Longitudinal association analyses were performed
using data from the sub-cohort of unrelated participants
aged 18-80 years and, for the case of the fasting glucose
outcome variable only, on the non-diabetic subset. The
outcome variables tested were fasting glucose, HDL and
Table 2 Description of BHS populations of participants aged 18-80 years, for variables with longitudinal data, at the
time of first assessment
a
Variable (units) Unrelated population (n = 2,864),
mean (SD)
Unrelated male population (n = 1,234),
mean (SD)
Unrelated female population (n =
1,630), mean (SD)
Age (years) 37.8 (11.6) 38.1 (11.6) 37.6 (11.6)
BMI (kg/m
2) 24.3 (3.6) 24.9 (3.2) 23.8 (3.8)
Fasting glucose
(mmol/l)
5.0 (1.1) 5.2 (1.4) 4.8 (0.8)
Triacylglycerol
(mmol/l)
1.2 (0.8) 1.4 (1.0) 1.1 (0.6)
HDL (mmol/l) 1.4 (0.4) 1.3 (0.3) 1.6 (0.4)
Total cholesterol
(mmol/l)
5.6 (1.2) 5.6 (1.2) 5.6 (1.2)
a Originally published as Table 2 in Webster RJ, Warrington NM, Weedon MN, Hattersley AT, McCaskie PA, Beilby JP, Palmer LJ, Frayling TM: The associationo f
common genetic variants in the APOA5, LPL and GCK genes with longitudinal changes in metabolic and cardiovascular traits. Diabetologia 2009, 52(1):106-114,
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transformed prior to analysis. The age, time and BMI
covariates were mean-centred. Longitudinal association
analyses were conducted using linear mixed-effects
models [31] with time × SNP and age × SNP interaction
terms, using the SimHap program. Covariates were
selected through a process of stepwise elimination as
described above. Genotypes were coded into three
classes (major allele homozygote = 0, heterozygote = 1
or minor allele homozygote = 2) and analysed under a
co-dominant genetic model. The results were used to
identify significant associations and investigate the most
appropriate genetic model for each case. The results of
the co-dominant model analyses are presented due to
the difficulty in assigning a more appropriate model in
the majority of cases.
Statistical power
All power calculations were performed using the Quanto
v1.2.3 software [32]. For all SNPs, analyses of BMI and
fasting glucose had at least 80% power at an alpha level
of p = 0.05 to detect a difference in beta coefficient of
0.010 and 0.013 (log-transformed units) respectively, for
the case of longitudinal analyses of the unrelated sub-
cohort, and 0.014 and 0.011 (log-transformed units)
respectively, for the case of cross-sectional analyses of
the whole cohort, under additive genetic models.
Results
Population characteristics
Genotypic and allelic frequencies for all eight SNPs in the
BHS populations are given in Additional file 1: Electronic
Supplementary Material (ESM) Table 1. No significant
deviation of allele frequencies from Hardy-Weinberg
equilibrium was observed in either the whole study
cohort or the unrelated sub-cohort for any of the SNPs.
Call rates for each SNP, validated through sequencing,
are also given in Additional file 1: ESM Table 1. Call
rates exceeded 99% for all SNPs.
Cross-sectional association of SNPs with metabolic and
cardiovascular traits
The results of cross-sectional total association analyses
of the whole cohort (n = 4,554) at the 1994/95 survey
for the fasting glucose and BMI outcomes are given in
Table 3. In analyses using full covariate models, we
observed that the T T2D-risk allele at the IGF2BP2 SNP
rs4402960 was associated with raised fasting glucose
level (p = 0.045), and that the A obesity-risk allele at the
FTO SNP rs9939609 was associated with raised BMI
(p = 0.003). Similar results were obtained using the
simple covariate model. In multivariate cross-sectional
analyses of traits in the sub-cohort of unrelated indivi-
duals at the 1994/95 survey, we observed that, under an
additive genetic model, rs4402960 explained 0.1% of var-
iation in fasting glucose level in unrelated non-diabetic
participants (n = 2,583). There was no significant asso-
ciation between BMI and rs9939609 in the unrelated
sub-cohort at the 1994/95 survey (n = 2,864), and the
percentage of variance in BMI explained by rs9939609
in this sub-cohort was estimated to be 0%.
The results of cross-sectional total association analyses
performed with additional metabolic and cardiovascular
outcomes are given in Additional file 1: ESM Table 2. In
analyses using full covariate models, we observed that the
C T2D-risk allele at the CDKAL1 SNP rs10946398 was
associated with reduced HOMA2-%B (p =0 . 0 1 ) ;t h a tt h e
major C T2D-risk allele at the SLC30A8 SNP rs13266634
was associated with reduced HOMA2-%B (p = 0.03); that
the major C T2D-risk allele at the PPARG SNP
rs1801282 was associated with reduced HOMA2-%S (p =
0.01) and raised fasting insulin level (p = 0.01); that the
major G T2D-risk allele at the HHEX SNP rs1111875
was associated with raised HOMA2-%S (p = 0.01) and
reduced fasting insulin level (p = 0.01); that the T T2D-
risk allele at the KCNJ11 SNP rs5219 was associated with
reduced BMI (p = 0.001); that the T T2D-risk allele the
TCF7L2 SNP at rs7903146 was associated with raised
triacylglycerol (p = 0.01) and LDL levels (p = 0.01); and
that the T T2D-risk allele at the IGF2BP2 SNP
rs4402960 was associated with raised triacylglycerol level
(p = 0.001). Similar results were obtained using the
simple covariate model (data not shown).
The results of cross-sectional association analyses of
the binary outcomes history of diabetes, and obesity
are given in Additional file 1: ESM Table 3. The
C T2D-risk allele at the PPARG SNP rs1801282, the
T T2D-risk allele at the TCF7L2 SNP rs7903146, and
the T T2D-risk allele at the IGF2BP2 SNP rs4402960
were significantly associated with T2D (p =0 . 0 4 9 6 ,p =
0.039, p = 0.022, respectively), with odds ratios of 1.46
(95% CI 1.00-2.12), 1.27 (95% CI 1.01-1.60) and 1.30
(95% CI 1.04-1.63) per risk allele, respectively. There
was no significant association of the KCNJ11 SNP
rs5219, the CDKAL1 SNP rs10946398, the SLC30A8
SNP rs13266634, the HHEX SNP rs1111875, or the
FTO SNP rs9939609 with T2D. Analysis of the obesity
outcome showed that the FTO SNP rs9939609 was not
significantly associated with obesity (p = 0.457). Similar
results were obtained using the simple covariate model
(data not shown).
Longitudinal association of SNPs with metabolic and
cardiovascular traits
The results of longitudinal association analyses for the
fasting glucose level and BMI outcomes are given in
Table 4. For each of these analyses, fitted values, calcu-
lated according to the co-dominant genetic models
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Figures 1 and 2.
For longitudinal analyses of the fasting glucose level
outcome, the SNP simple effects (non-interaction)
results showed no significant associations of any of the
seven SNPs with fasting glucose in the unrelated sub-
cohort (data not shown). The SNP interaction results
showed no strong evidence of effect sizes varying with
age (from 18-80 years) or time (from 1975-1994/5).
Analysis of rs1111875 with fasting glucose under a co-
dominant model showed a significant association of the
age × rs1111875 (heterozygote vs major homozygote)
interaction term with fasting glucose level (Table 4; p =
0.03), suggesting that one copy of the A non-risk allele
at rs1111875 increases fasting glucose level with increas-
ing age. However, under an additive genetic model,
deemed to be the most likely genetic model for this par-
ticular association based on the co-dominant model
results, the age × rs1111875 interaction term was not
significantly associated with fasting glucose level, indi-
cating that there is no significant overall linear trend in
the effect size of rs1111875 genotype on fasting glucose
level with age.
In longitudinal analyses of BMI, rs9939609 simple
effects were found to be significant, with the rs9939609
minor homozygote vs major homozygote term being sig-
nificantly associated with raised BMI under a co-domi-
nant model (p = 0.003), and the rs9939609 term being
significantly associated with raised BMI under the best-
fitting recessive model (p = 0.004). This indicates that
the A allele at rs9939609 is significantly associated with
raised BMI in the unrelated sub-cohort, when data from
all surveys are considered. However, there was no evi-
dence for longitudinal variation in the effect size of
rs9939609 genotype on BMI, either over time or with
age from 18-80 years.
Longitudinal association analysis results for lipid level
and BMI outcomes with all SNPs are given in Addi-
tional file 1: ESM Table 4. We observed some evidence
for increasing effect sizes of the T risk alleles at
rs7903146 and rs4402960 on triacylglycerol level with
time and age respectively, and for a decreasing effect
size of the C risk allele at rs13266634 on triacylglycerol
level with age. We also observed some evidence that the
effect sizes of the risk C alleles at rs1801282 and
rs13266634 on HDL varied with both age and time, a
decreasing effect with age and increasing effect with
time for the case of rs1801282, and an increasing effect
with age and decreasing effect with time for the case of
rs13266634. There was also some evidence that the
effect size of the G risk allele at rs1111875 on BMI
decreased with age and increased with time.
Discussion
While the number of genetic variants confirmed to be
associated with T2D is growing, the relationships
between these variants and T2D intermediate phenotypes
are yet to be fully characterised, particularly longitudin-
ally. In this study, we investigated the cross-sectional and
longitudinal associations of seven T2D-susceptibility var-
iants in the KCNJ11, PPARG, TCF7L2, IGF2BP2,
CDKAL1, SLC30A8 and HHEX genes with fasting glucose
level, and of another in the FTO gene with BMI, in a
large, population-based European-Australian cohort.
Our cross-sectional analyses showed that, of the seven
SNPs analysed with the fasting glucose outcome, only the
IGF2BP2 SNP rs4402960 showed a significant result, the
T allele at this SNP being nominally associated with
Table 3 Results of cross-sectional association analyses of fasting glucose and BMI
a
Full covariate model
b Simple covariate model
c
Gene SNP Risk allele (frequency) Per risk allele effect size p Per risk allele effect size p
Fasting glucose
KCNJ11 rs5219 T (0.363) 0.001 0.70 -0.001 0.75
PPARG rs1801282 C (0.883) 0.003 0.56 0.011 0.05
TCF7L2 rs7903146 T (0.303) 0.003 0.44 0.006 0.12
IGF2BP2 rs4402960 T (0.304) 0.007 0.045* 0.011 0.01*
CDKAL1 rs10946398 C (0.303) 0.006 0.08 0.003 0.42
SLC30A8 rs13266634 C (0.699) 0.007 0.05 0.005 0.18
HHEX rs1111875 G (0.584) -0.002 0.51 -0.003 0.40
BMI
FTO rs9939609 A (0.409) 0.009 0.003* 0.013 0.0003*
a Analyses were conducted on data from the whole study population (n = 4,554) at the 1994/95 survey.
b Phenotype adjustments, full covariate model:
Fasting glucose: sex, age, age squared, BMI, fasting insulin, SBP, history of diabetes.
BMI: sex, age, age squared, fasting insulin, HDL, SBP, DBP.
c Phenotype adjustments for all outcomes, simple covariate model: sex, age.
* p < 0.05.
Webster et al. BMC Medical Genetics 2010, 11:140
http://www.biomedcentral.com/1471-2350/11/140
Page 5 of 10raised fasting glucose (p = 0.045). Though some previous
studies have reported significant associations of
rs4402960, rs7903146 and rs13266634 with raised fasting
glucose [33-36], others find no significant associations
between these three SNPs and fasting glucose in their
populations [33,34,37-40]. Studies of the SNPs rs5219,
rs1801282, rs10946398 and rs1111875 have also shown
no significant associations with fasting glucose
[17,33,34,38,40-44]. Rather, the majority of evidence from
previous studies suggests that these seven SNPs alter
T2D susceptibility through effects on insulin sensitivity
(rs1801282 [45]) or pancreatic beta cell function (rs5219,
rs7903146, rs10946398, rs4402960, rs13266634 and
rs1111875 [34,36,38,46-52]). Indeed, we did observe asso-
ciations of the risk allele at the PPARG SNP rs1801282
with lower HOMA2-%S (p =0 . 0 1 ) ,a n do ft h er i s ka l l e l e s
at the CDKAL1 SNP rs10946398 and the SLC30A8 SNP
rs13266634 with lower HOMA2-%B (p =0 . 0 1a n d
p = 0.03, respectively). Fasting glucose level may reflect
abnormalities in insulin sensitivity and beta cell function,
and is a useful clinical indicator of diabetes. However, it
is dependent on a number of other factors, e.g. the site of
insulin insensitivity [53], which may have influenced the
results here. It may also be that effects on fasting glucose
are more subtle than may be detected with the available
power. We also did not observe significant associations
of the SNPs rs5219, rs10946398, rs1111875 or rs9939609
with T2D, likely due in part to the small number of dia-
betic participants in our cohort.
Associations may also be more difficult to detect if SNP
effects vary with factors such as other gene variants, life-
style factors and age. If a SNP has an age-varying effect
on a particular trait, such as an effect to raise fasting
glucose level as of middle age for example, then cross-
sectional analysis of participants of all ages may miss the
association. On the other hand, longitudinal analysis may
Table 4 Results of longitudinal association analyses of fasting glucose and BMI
a
Age × SNP interaction Time × SNP interaction
Gene SNP (Risk allele,
frequency)
Factor Beta (95% CI) p Beta (95% CI) p
Fasting glucose
b (loge[mmol/l])
KCNJ11 rs5219 CC Baseline
(T, 0.355) CT 7.0 × 10
-5 (-4.6 × 10
-4, 6.0 × 10
-4) 0.79 -5.3 × 10
-4 (-1.3 × 10
-3, 2.6 × 10
-4) 0.19
TT -4.3 × 10
-4 (-1.2 × 10
-3, 3.3 × 10
-4) 0.27 -6.8 × 10
-4 (-1.8 × 10
-3, 4.8 × 10
-4) 0.25
PPARG rs1801282 CC Baseline
(C, 0.881) CG 8.0 × 10
-5 (-5.2 × 10
-4, 6.8 × 10
-4) 0.79 -3.6 × 10
-4 (-1.3 × 10
-3, 5.4 × 10
-4) 0.43
GG -8.8 × 10
-4 (-3.0 × 10
-3, 1.2 × 10
-3) 0.41 3.7 × 10
-4 (-2.8 × 10
-3, 3.6 × 10
-3) 0.82
TCF7L2 rs7903146 CC Baseline
(T, 0.300) CT -1.2 × 10
-4 (-6.3 × 10
-4, 4.0 × 10
-4) 0.65 -3.2 × 10
-4 (-1.1 × 10
-3, 4.5 × 10
-4) 0.41
TT 7.3 × 10
-4 (-1.6 × 10
-4, 1.6 × 10
-3) 0.11 5.6 × 10
-4 (-8.0 × 10
-4, 1.9 × 10
-3) 0.42
IGF2BP2 rs4402960 GG Baseline
(T, 0.314) GT -3.8 × 10
-5 (-5.5 × 10
-4, 4.8 × 10
-4) 0.89 6.3 × 10
-4 (-1.5 × 10
-4, 1.4 × 10
-3) 0.12
TT 4.7 × 10
-4 (-4.1 × 10
-4, 1.4 × 10
-3) 0.30 -4.0 × 10
-4 (-1.7 × 10
-3, 9.1 × 10
-4) 0.55
CDKAL1 rs10946398 AA Baseline
(C, 0.308) AC 4.9 × 10
-5 (-4.7 × 10
-4, 5.7 × 10
-4) 0.85 2.1 × 10
-4 (-5.7 × 10
-4, 9.9 × 10
-4) 0.60
CC -3.3 × 10
-4 (-1.2 × 10
-3, 5.0 × 10
-4) 0.43 -3.6 × 10
-4 (-1.6 × 10
-3, 9.1 × 10
-4) 0.58
SLC30A8 rs13266634 CC Baseline
(C, 0.696) CT 2.4 × 10
-5 (-4.9 × 10
-4, 5.4 × 10
-4) 0.93 1.4 × 10
-4 (-6.4 × 10
-4, 9.1 × 10
-4) 0.73
TT 8.0 × 10
-4 (-5.2 × 10
-5, 1.7 × 10
-3) 0.07 -1.2 × 10
-4 (-1.4 × 10
-3, 1.2 × 10
-3) 0.86
HHEX rs1111875 GG Baseline
(G, 0.578) GA 6.1 × 10
-4 (6.3 × 10
-5, 1.2 × 10
-3) 0.03* -2.3 × 10
-4 (-1.0 × 10
-3, 6.0 × 10
-4) 0.59
AA -2.3 × 10
-4 (-9.3 × 10
-4, 4.8 × 10
-4) 0.53 2.4 × 10
-4 (-8.2 × 10
-4, 1.3 × 10
-3) 0.65
BMI
b (loge[kg/m
2])
FTO rs9939609 TT Baseline
(A, 0.402) TA 2.6 × 10
-4 (-4.7 × 10
-4, 9.9 × 10
-4) 0.49 2.1 × 10
-5 (-7.7 × 10
-4, 8.1 × 10
-4) 0.96
AA -2.0 × 10
-5 (-1.0 × 10
-3, 9.9 × 10
-4) 0.97 -2.8 × 10
-4 (-1.4 × 10
-3, 8.1 × 10
-4) 0.61
a BMI outcome analyses were conducted on data from unrelated participants aged 18-80 years (n = 2,864). Fasting glucose outcome analyses were conducted on
data from the subset of non-diabetic participants (n = 2,583). Results are for age × SNP and time × SNP interaction terms with co-dominant genetic models.
b Phenotype adjustments:
Fasting glucose: sex, age, BMI, age at first survey, time of survey.
BMI: sex, age, age × sex, smoking status, age at first survey, time of survey.
*p < 0.05.
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Page 6 of 10Figure 1 Variation with age of adjusted, natural log-transformed fasting glucose by genotype. Data is from unrelated, non-diabetic
participants aged 18-80 years (n = 2,583), for seven SNPs: (a) KCNJ11 SNP rs5219, (b) PPARG SNP rs1801282, (c) TCF7L2 SNP rs7903146, (d) IGF2BP2
SNP rs4402960, (e) CDKAL1 SNP rs10946398, (f) SLC30A8 SNP rs13266634, (g) HHEX SNP rs1111875. Values were fitted using co-dominant genetic
models.
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Page 7 of 10still identify the relationship, by examining the associa-
tion of the combination of SNP allele and age with phe-
notype in aging individuals, through a SNP × age
interaction term. However, in our longitudinal analyses
of SNPs with fasting glucose level, we found no evidence
of changes in associations either with age or over time,
indicating that these SNPs are not involved in the age-
related increase in fasting glucose level, and that their
effects are not influenced by any environmental factors
that have changed over the ~20 year time period exam-
ined. The curves of Figure 1 depict these results, gener-
ally showing no significant differences in the rates at
which fasting glucose level increases with age for the
three genotype groups of each SNP, although it is impor-
tant to note again that we did not see strong evidence for
cross-sectional differences.
Our investigation of the FTO SNP rs9939609 showed
no significant association with obesity. However, we did
confirm that the A allele at rs9939609 was significantly
associated with raised BMI, both in cross-sectional ana-
lyses of the whole adult study population (p =0 . 0 0 3 ) ,
and in analyses of the unrelated sub-cohort performed
across all surveys (p = 0.004). The association between
FTO variants and BMI is not in doubt, and has been
described both in childhood and old age [11,14-16,54].
For the rs9939609 SNP, an effect size of about 0.4 kg/
m
2 per susceptibility allele has been reported [14]. But
does this effect size alter with age? We found no signifi-
cant evidence of this in our analysis of the rs9939609
SNP in the unrelated study population. Several other
studies of the longitudinal effects of FTO on BMI have
been conducted. Some of these have reported different
effects at different ages, but these findings were often
limited to one sex or another subgroup after a primary
analysis, and chance may have influenced these results
[8,11-13]. The evidence that FTO has different effects
on BMI at different ages or at different times is there-
fore weak and further studies are needed.
Differences between the findings of this and other stu-
dies may have arisen from numerous sources. Most
likely chance has played a strong role. Moreover, this
study is underpowered to detect small to moderate
genetic effects. Hence, the failure to observe significant
associations must be interpreted in this light. Differences
in factors that may interact with genotype but were not
controlled for, e.g. lifestyle factors such as diet and phy-
sical activity, may also have influenced the results, as
may have differences in the ethnic compositions of the
cohorts studied. The risk allele frequencies of all eight
SNPs in the BHS cohort studied here (Additional file 1:
ESM Table 1) are comparable to those in European
populations, as reported in the dbSNP database http://
www.ncbi.nlm.nih.gov/projects/SNP/.
It is clear that further studies are required to assess the
validity of our longitudinal findings. These would ideally
address the issues of analytic power and additional cov-
ariates, and test the generalisability of our results to
populations from diverse ethnic backgrounds. In addi-
tion, though the average follow-up times of 18.7 years for
fasting glucose level and 21.8 years for BMI enable an
extended longitudinal analysis to be conducted, they can-
not provide as complete a picture of age-related changes
a sw o u l dc o m ef r o mas t u d yt h a tf o l l o w e dp a r t i c i p a n t s
t h r o u g hf r o my o u t ht oo l da g e .H o w e v e r ,t oo u rk n o w l -
edge, few longer running longitudinal surveys of the
same individuals are able to address these longitudinal
questions, and the BHS provides phenotypic data that is
particularly comprehensive. The understanding of the
function of the T2D-susceptibility SNPs studied here
would also benefit from longitudinal analysis of addi-
tional metabolic traits, such as glucose tolerance test 30
minute and 2 hour glucose levels, which would provide
further information on their relationship to impaired glu-
cose tolerance.
Conclusions
In conclusion, the results of this study showed no indi-
cation that the effects of seven common T2D suscept-
ibility variants on fasting glucose level or the effect of
the FTO SNP rs9939609 on BMI varied with age during
adulthood or over time. However, the results should be
interpreted with caution due to power considerations.
The potential consequences of longitudinal associations
on phenotypic traits and their treatment across the life-
span highlight the need for replication and further char-
acterisation studies.
Figure 2 Variation with age of adjusted, natural log-
transformed BMI by rs9939609 genotype. Data is from unrelated
participants aged 18-80 years (n = 2,864). Values were fitted using a
co-dominant genetic model.
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